Open AccessCoronavirus Disease 2019-Associated Pulmonary Aspergillosis
Author(s) -
Young Hoon Hwang,
Sang-Won Park
Publication year - 2022
Publication title -
korean journal of medical mycology/daehan'yi jin'gyun haghoeji
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.101
H-Index - 9
eISSN - 2465-8278
pISSN - 1226-4709
DOI - 10.17966/jmi.2022.27.1.1
Subject(s) - aspergillosis , pandemic , incidence (geometry) , infectious disease (medical specialty) , intensive care medicine , medicine , pulmonary aspergillosis , covid-19 , intensive care , disease , coronavirus , immunology , pathology , physics , optics
As the coronavirus disease 2019 (COVID-19) pandemic continues, a new disease, COVID-19-associated pulmonaryaspergillosis (CAPA), is on the rise. CAPA is a secondary fungal infection in patients with critical COVID-19 receivingmechanical ventilation in intensive care units (ICUs). Although the incidence rate of CAPA is estimated to be 10.2%in ICU patients, CAPA appears to be associated with an increase in overall mortality. CAPA is like classical invasivepulmonary aspergillosis (IPA) but has an ambiguous clinical manifestation and occurs without typical host factors.It is also like influenza-associated pulmonary aspergillosis but differs in clinical characteristics. For research andclinical practice, the European Confederation for Medical Mycology and the International Society for Human andAnimal Mycology proposed novel case definition criteria for CAPA. Although CAPA management is not muchdifferent from typical IPA, areas of uncertainty remain that require further investigation.